Evidence map›Paper›PMID 37305871›Full record

ArticleClinical case reports2023

Pathologic complete response to neoadjuvant imatinib of a gastric stromal tumor with concomitant mutations in

Mariem Ben Rekaya, Feryel Ksontini, Linda Bel Haj Kacem, Farah Sassi, Emna Harigua-Souiai, Ryma Boujneh, Ahmed H'mayada, Yosra Zaimi, Mouna Ayadi, Mediha Trabelsi and 2 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Mariem Ben RekayaTheranostic Biomarkers, UR17ES15, Faculty of Medicine of Tunis Université Tunis El Manar Tunis Tunisia.
Feryel KsontiniMedical Oncology Department Salah Azaiez Institute Tunis Tunisia.
Linda Bel Haj KacemTheranostic Biomarkers, UR17ES15, Faculty of Medicine of Tunis Université Tunis El Manar Tunis Tunisia.
Farah SassiPathology Department Charles Nicolle Hospital Tunis Tunisia.ORCID https://orcid.org/0000-0003-2078-6795
Emna Harigua-SouiaiLaboratory of Molecular Epidemiology and Experimental Pathology - LR16IPT04 Institut Pasteur de Tunis, Université de Tunis El Manar Tunis Tunisia.
Ryma BoujnehMedical Oncology Department Salah Azaiez Institute Tunis Tunisia.
Ahmed H'mayadaTheranostic Biomarkers, UR17ES15, Faculty of Medicine of Tunis Université Tunis El Manar Tunis Tunisia.
Yosra ZaimiGastroenterology Department Charles Nicolle Hospital Tunis Tunisia.
Mouna AyadiMedical Oncology Department Salah Azaiez Institute Tunis Tunisia.
Mediha TrabelsiDepartment of Hereditary and Congenital Disorders Charles Nicolle Hospital Tunis Tunisia.
Ridha MradDepartment of Hereditary and Congenital Disorders Charles Nicolle Hospital Tunis Tunisia.
Soumaya RammehTheranostic Biomarkers, UR17ES15, Faculty of Medicine of Tunis Université Tunis El Manar Tunis Tunisia.
Hôpital Charles-Nicolle · TNInstitut Salah-Azaïz · TNFaculté de médecine de TunisTunis University · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Key clinical message: We report the first case of pathologic complete response (pCR) to neoadjuvant imatinib in a gastric stromal tumor harboring Abstract: pCR of GIST to neoadjuvant imatinib is rare. We report a case of pCR to neoadjuvant imatinib in a gastric stromal tumor that harbored co-occurrence of multiple

Indexed as

imatinibKITmutationpathologic complete responsePDGFRA

Identifiers

PMID37305871
PMCPMC10248213
OpenAlexW4379882845

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.